{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:15:44Z","timestamp":1767665744454,"version":"3.41.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["NO. 19JCYBJC26500"],"award-info":[{"award-number":["NO. 19JCYBJC26500"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["NO. Y-XD2019-162"],"award-info":[{"award-number":["NO. Y-XD2019-162"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013279","name":"National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Although the role of tumor-infiltrating T cells in follicular lymphoma (FL) has been reported previously, the prognostic value of peripheral blood T lymphocyte subsets has not been systematically assessed. Thus, we aim to incorporate T-cell subsets with clinical features to develop a predictive model of clinical outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively screened a total of 1,008 patients, including 252 newly diagnosed <jats:italic>de novo<\/jats:italic> FL patients with available peripheral blood T lymphocyte subsets who were randomized to different sets (177 in the training set and 75 in the internal validation set). A nomogram and a novel immune-clinical prognostic index (ICPI) were established according to multivariate Cox regression analysis for progression-free survival (PFS). The concordance index (C-index), Akaike\u2019s information criterion (AIC), and likelihood ratio chi-square were employed to compare the ICPI\u2019s discriminatory capability and homogeneity to that of FLIPI, FLIPI2, and PRIMA-PI. Additional external validation was performed using a dataset (n = 157) from other four centers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the training set, multivariate analysis identified five independent prognostic factors (Stage III\/IV disease, elevated lactate dehydrogenase (LDH), Hb &amp;lt;120g\/L, CD4+ &amp;lt;30.7% and CD8+ &amp;gt;36.6%) for PFS. A novel ICPI was established according to the number of risk factors and stratify patients into 3 risk groups: high, intermediate, and low-risk with 4-5, 2-3, 0-1 risk factors respectively. The hazard ratios for patients in the high and intermediate-risk groups than those in the low-risk were 27.640 and 2.758. The ICPI could stratify patients into different risk groups both in the training set (P &amp;lt; 0.0001), internal validation set (P = 0.0039) and external validation set (P = 0.04). Moreover, in patients treated with RCHOP-like therapy, the ICPI was also predictive (P &amp;lt; 0.0001). In comparison to FLIPI, FLIPI2, and PRIMA-PI (C-index, 0.613-0.647), the ICPI offered adequate discrimination capability with C-index values of 0.679. Additionally, it exhibits good performance based on the lowest AIC and highest likelihood ratio chi-square score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The ICPI is a novel predictive model with improved prognostic performance for patients with <jats:italic>de novo<\/jats:italic> FL treated with R-CHOP\/CHOP chemotherapy. It is capable to be used in routine practice and guides individualized precision therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.708784","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T14:04:07Z","timestamp":1626185047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP\/CHOP Chemotherapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Yaxiao","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengzi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx189","article-title":"Unmet Needs in the First-Line Treatment of Follicular Lymphoma","volume":"28","author":"Casulo","year":"2017","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.91","article-title":"How We Manage Follicular Lymphoma","volume":"28","author":"Hiddemann","year":"2014","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic Factors in Follicular Lymphoma","volume":"28","author":"Relander","year":"2010","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63186","article-title":"Pathogenesis of Follicular Lymphoma","volume":"122","author":"Kridel","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline Therapy With Rituximab Added to the Combination of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Significantly Improves the Outcome for Patients With Advanced-Stage Follicular Lymphoma Compared With Therapy With CHOP Alone: Results of a Prospective Randomized Study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO Guidelines Consensus Conference on Malignant Lymphoma 2011 Part 1: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL) and Chronic Lymphocytic Leukemia (CLL)","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) Separates High-Risk From Intermediate- or Low-Risk Patients With Advanced-Stage Follicular Lymphoma Treated Front-Line With Rituximab and the Combination of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) With Respect to Treatment Outcome","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx496","article-title":"A Phase II Trial of Lenalidomide Plus Rituximab in Previously Untreated Follicular Non-Hodgkin\u2019s Lymphoma (NHL): CALGB 50803 (Alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and Activity of Lenalidomide and Rituximab in Untreated Indolent Lymphoma: An Open-Label, Phase 2 Trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp460","article-title":"Prognostic Value of Regulatory T Cells, Lymphoma-Associated Macrophages, and MUM-1 Expression in Follicular Lymphoma Treated Before and After the Introduction of Monoclonal Antibody Therapy: A Southwest Oncology Group Study","volume":"21","author":"Sweetenham","year":"2010","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in Low-Tumor-Burden Follicular Lymphomas Between an Initial No-Treatment Policy, Prednimustine, or Interferon Alfa: A Randomized Study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-799080","article-title":"FOXP1 Expression Is a Prognostic Biomarker in Follicular Lymphoma Treated With Rituximab and Chemotherapy","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","article-title":"Genomic Alterations Important for the Prognosis in Patients With Follicular Lymphoma Treated in SWOG Study S0016","volume":"133","author":"Qu","year":"2019","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of Gene Mutations in Risk Prognostication for Patients Receiving First-Line Immunochemotherapy for Follicular Lymphoma: A Retrospective Analysis of a Prospective Clinical Trial and Validation in a Population-Based Registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic Risk Models Predict Early Progression of Follicular Lymphoma After First-Line Immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A Gene-Expression Profiling Score for Prediction of Outcome in Patients With Follicular Lymphoma: A Retrospective Training and Validation Analysis in Three International Cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126233","article-title":"Intrafollicular CD4+ T-Cells as an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma","volume":"134","author":"Mondello","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16414","article-title":"Prognostic Implications of the Microenvironment for Follicular Lymphoma Under Immunomodulation Therapy","volume":"189","author":"Menter","year":"2020","journal-title":"Brit J Haematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/joim.12608","article-title":"Early Stages in the Ontogeny of Small B-Cell Lymphomas: Genetics and Microenvironment","volume":"282","author":"Ghia","year":"2017","journal-title":"J\u00a0Intern Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.02.007","article-title":"The Microenvironment in Follicular Lymphoma","volume":"24","author":"de Jong","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000440","article-title":"Microenvironment Signaling Driving Lymphomagenesis","volume":"25","author":"Verdiere","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2298","article-title":"Gene Expression Profiling in Follicular Lymphoma to Assess Clinical Aggressiveness and to Guide the Choice of Treatment","volume":"105","author":"Glas","year":"2005","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4766","article-title":"Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma Patients","volume":"24","author":"Alvaro","year":"2006","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2487","article-title":"A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1-Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages","volume":"16","author":"Wahlin","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165415","article-title":"Prognostic Relevance of CD163 and CD8 Combined With EZH2 and Gain of Chromosome 18 in Follicular Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium","volume":"102","author":"Stevens","year":"2017","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.720","article-title":"CD4+T-Cell Immune Response to Large B-Cell Non-Hodgkin\u2019s Lymphoma Predicts Patient Outcome","volume":"19","author":"Ansell","year":"2001","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i45.7233","article-title":"Colon Cancer and the Immune System: The Role of Tumor Invading T Cells","volume":"12","author":"Waldner","year":"2006","journal-title":"World J Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.11.005","article-title":"Low Level of Blood CD4(+) T Cells Is An Independent Predictor of Inferior Progression-Free Survival in Diffuse Large B-Cell Lymphoma","volume":"17","author":"Judd","year":"2017","journal-title":"Cl Lymph Myelom Leuk"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0176-1","article-title":"Prognostic Significance of T Cell Subsets in Peripheral Blood of B Cell Non-Hodgkin\u2019s Lymphoma Patients","volume":"29","author":"Dehghani","year":"2012","journal-title":"Med Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3148","article-title":"Selection of Important Variables and Determination of Functional Form for Continuous Predictors in Multivariable Model Building","volume":"26","author":"Sauerbrei","year":"2007","journal-title":"Stat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705","article-title":"A New Look at the Statistical Model Identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automat Contr"},{"key":"B35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0049124104268644","article-title":"Multimodel Inference: Understanding AIC and BIC in Model Selection","volume":"33","author":"Burnham KP","year":"2004","journal-title":"Sociol Methods Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2929","article-title":"Evaluating the Added Predictive Ability of a New Marker: From Area Under the ROC Curve to Reclassification and Beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"volume-title":"Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach","year":"2002","author":"Burnham KP","key":"B37"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13020","article-title":"Negative Prognostic Impact of Low Absolute CD4(+) T Cell Counts in Peripheral Blood in Mantle Cell Lymphoma","volume":"107","author":"Zhang","year":"2016","journal-title":"Cancer Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.010","article-title":"Circulating Low Absolute CD4(+) T Cell Counts May Predict Poor Prognosis in Extranodal Nk\/T-Cell Lymphoma Patients Treating With Pegaspargase-Based Chemotherapy","volume":"51","author":"Zhang","year":"2019","journal-title":"Cancer Res Treat"},{"key":"B42","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00277-021-04474-3","article-title":"Circulating Low CD4(+)\/CD8(+) Ratio Is Associated With Poor Prognosis in Waldenstrom Macroglobulinemia Patients","volume":"4","author":"Cao","year":"2021","journal-title":"Ann Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.263194","article-title":"Baseline SUVmax is Related to Tumor Cell Proliferation and Patient Outcome in Follicular Lymphoma","author":"Rossi","year":"2020","journal-title":"Haematologica"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001609","article-title":"Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biological Therapy","volume":"45","author":"Sohani","year":"2021","journal-title":"Am J Surg Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.708784\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T14:04:25Z","timestamp":1626185065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.708784\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":44,"alternative-id":["10.3389\/fonc.2021.708784"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.708784","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"article-number":"708784"}}